PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Phase 2 Unknown 35 enrolled Sun Yat-sen University China Food and Drug Administration · collab

NaSingle-groupOpen-labelTreatment

Summary

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of pegylated aspargase(PEG-ASP)combined with etoposide and gemcitabine (PEG) treatment in this population.

Timeline

Start: 2016-02
Primary completion: 2023-12
Completion: 2023-12

Publications

Feng D, Yan Z, Fu B, Bai S, Zhu L, Gale RP, Xia Z, Liang Y, Wang H. Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma. Hematology. 2024 Dec;29(1):2402102. doi: 10.1080/16078454.2024.2402102. Epub 2024 Sep 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etoposide	Small molecule	100 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Pegaspargase	Protein / enzyme biologic	2500 unknown	Intramuscular

Indications

No indication recorded.